Folch Ibáñez Jordi, Vargas Domingo Maribel, Coma Alemany Joan, Callao Sánchez Roger, Guitart Vela Jordi
Unit of Pain Pathology, Department of Anesthesiology, Resuscitation and Pain Management, Hospital Plató, 08006 Barcelona, Spain.
Unit of Pain Pathology, Department of Anesthesiology, Resuscitation and Pain Management, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, 08830 Barcelona, Spain.
J Clin Med. 2025 Jun 25;14(13):4487. doi: 10.3390/jcm14134487.
: The joint presence of chronic pain (CP) and depression is frequent, exacerbating symptoms of both conditions. Although tricyclic antidepressants and serotonin noradrenaline reuptake inhibitors are effective treatments, they are frequently not well tolerated, and selective serotonin reuptake inhibitors are not useful for controlling CP. This study investigated vortioxetine's effectiveness in relieving CP in patients with any degree of depression. : Patient data with any degree of depression and with CP (Visual Analog Scale [VAS] score ≥ 4) were collected and analyzed. Included patients (n = 142) were initially treated with vortioxetine 10 mg/day for 3 months. Improvement of patients' pain and condition was measured with the VAS, Patient Global Impression (PGI), and Clinical Global Impression (CGI) scales at 1 and 3 months. Brief Pain Inventory (BPI) was measured at baseline and 3 months. Additionally, at baseline and after 3 months of treatment, the Satisfaction with Medicines Questionnaire (SATMED-Q) and 9-item Patient Health Questionnaire (PHQ-9) were evaluated. Adverse Events (AEs) were recorded. : Patients showed significant improvement ( < 0.001) in VAS from baseline to 1 and 3 months (mean [SD]: 7.19 [0.62], 6.23 [0.80], and 5.41 [1.15], respectively). BPI and PHQ-9 scores also showed a significant decrease from baseline (mean [SD] of 6.05 [0.75] and 11.73 [4.89], respectively) to 3 months (5.11 [1.04] and 6.95 [2.52], respectively). Clinical improvement with the CGI and PGI scales were reported. According to the SATMED-Q, patients were satisfied with the treatment. Only a few mild EAs were recorded. : Vortioxetine can improve both the severity and intensity of CP in patients with any degree of depression.
慢性疼痛（CP）与抑郁症常常共同存在，会加重这两种病症的症状。尽管三环类抗抑郁药和5-羟色胺去甲肾上腺素再摄取抑制剂是有效的治疗药物，但它们常常耐受性不佳，而选择性5-羟色胺再摄取抑制剂对控制慢性疼痛并无作用。本研究调查了伏硫西汀在缓解任何程度抑郁症患者慢性疼痛方面的有效性。收集并分析了患有任何程度抑郁症且伴有慢性疼痛（视觉模拟评分[VAS]≥4）的患者数据。纳入的患者（n = 142）最初接受每日10毫克伏硫西汀治疗，为期3个月。在1个月和3个月时，使用VAS、患者整体印象（PGI）和临床整体印象（CGI）量表来衡量患者疼痛和病情的改善情况。在基线和3个月时测量简明疼痛量表（BPI）。此外，在基线和治疗3个月后，评估药物满意度问卷（SATMED-Q）和9项患者健康问卷（PHQ-9）。记录不良事件（AE）。患者从基线到1个月和3个月时VAS有显著改善（<0.001）（均值[标准差]分别为：7.19 [0.62]、6.23 [0.80]和5.41 [1.15]）。BPI和PHQ-9评分从基线（均值[标准差]分别为6.05 [0.75]和11.73 [4.89]）到3个月时也显著降低（分别为5.11 [1.04]和6.95 [2.52]）。报告了CGI和PGI量表的临床改善情况。根据SATMED-Q，患者对治疗感到满意。仅记录到少数轻度不良事件。伏硫西汀可改善任何程度抑郁症患者慢性疼痛的严重程度和强度。
